Background
DNA vaccines offer several advantages over other vaccine concepts, but poor immunogenicity in clinical use is still a general concern. Therefore, strategies to optimize the immunogenicity of DNA vaccines are urgently needed. Here, we explored the efficacy of Bupivacaine on augmenting the immunogenicity of a DNA vaccine encoding multiple HIV epitopes designed by our group.